The blood metabolome of incident kidney cancer: A case-control study nested within the MetKid consortium.
Florence GuidaVanessa Y TanLaura J CorbinKarl Smith-ByrneKarine AlcalaClaudia LangenbergIsobel D StewartAdam S ButterworthPraveen SurendranDavid AchaintreJerzy AdamskiPilar AmianoManuela M BergmannCaroline J BullChristina Catherine DahmAudrey GicquiauGraham G GilesMarc J GunterToomas HallerArnulf LanghammerTricia L LaroseBörje LjungbergAndres MetspaluJonathan BeesleyDavid C MullerTherese Haugdhal NøstElin Pettersen SørgjerdCornelia PrehnElio RiboliSabina RinaldiJoseph A RothwellAugustin ScalbertJulie A SchmidtGianluca SeveriSabina SieriRoel VermeulenEmma E VincentMelanie WaldenbergerNicholas John TimpsonMattias J JohanssonPublished in: PLoS medicine (2021)
This study suggests a potentially important role of the blood metabolome in kidney cancer aetiology by highlighting a wide range of metabolites associated with the risk of developing kidney cancer and the extent to which changes in levels of these metabolites are driven by BMI-the principal modifiable risk factor of kidney cancer.